Injectable nano-in situ-thermosensitive-hydrogels based on halofuginone and silver for postoperative treatment against triple-negative breast cancer
Language English Country Netherlands Media print-electronic
Document type Journal Article
PubMed
38917957
DOI
10.1016/j.ijpharm.2024.124384
PII: S0378-5173(24)00618-5
Knihovny.cz E-resources
- Keywords
- Halofuginone, Injectable, Nano-in situ-thermosensitive-hydrogels, Postoperative, Silver, Triple-negative breast cancer,
- MeSH
- Quinazolinones * chemistry administration & dosage pharmacology MeSH
- Hydrogels * administration & dosage chemistry MeSH
- Metal Nanoparticles administration & dosage chemistry MeSH
- Humans MeSH
- Mice, Inbred BALB C MeSH
- Mice, Nude MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neovascularization, Pathologic drug therapy MeSH
- Piperidines * pharmacology administration & dosage chemistry MeSH
- Cell Movement drug effects MeSH
- Cell Proliferation * drug effects MeSH
- Antineoplastic Agents * administration & dosage pharmacology chemistry MeSH
- Silver * chemistry administration & dosage MeSH
- Triple Negative Breast Neoplasms * drug therapy MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Quinazolinones * MeSH
- halofuginone MeSH Browser
- Hydrogels * MeSH
- Piperidines * MeSH
- Antineoplastic Agents * MeSH
- Silver * MeSH
Postoperative distant metastasis and high recurrence rate causes a dilemma in treating triple-negative breast cancer (TNBC) owing to its unforeseeable invasion into various organs or tissues. The wealth of nutrition provided by vascular may facilitate the proliferation and angiogenesis of cancer cells, which further enhance the rates of postoperative metastasis and recurrence. Chemotherapy, as a systemic postoperative adjuvant therapy, is generally applied to diminish recurrence and metastasis of TNBC. Herein, an halofuginone-silver nano thermosensitive hydrogel (HTPM&AgNPs-gel) was prepared via a physical swelling method. The in vitro anticancer efficacy of HTPM&AgNPs-gel was analyzed by investigating cell proliferation, migration, invasion, and angiogenesis capacity. Furthermore, the in vivo anti-cancer activity of HTPM&AgNPs-gel was further appraised through the tumor suppression, anti-metastatic, anti-angiogenic, and anti-inflammatory ability. The optimized HTPM&AgNPs-gel, a thermosensitive hydrogel, showed excellent properties, including syringeability, swelling behavior, and a sustained release effect without hemolysis. In addition, HTPM&AgNPs-gel was confirmed to effectively inhibit the proliferation, migration, invasion, and angiogenesis of MDA-MB-231 cells. An evaluation of the in vivo anti-tumor efficacy demonstrated that HTPM&AgNPs-gel showed a stronger tumor inhibition rate (68.17%) than did HTPM-gel or AgNPs-gel used alone and exhibited outstanding biocompatibility. Notably, HTPM&AgNPs-gel also inhibited lung metastasis induced by residual tumor tissue after surgery and further blocked angiogenesis-related inflammatory responses. Taken together, the suppression of inflammation by interdicting the blood vessels adjoining the tumor and inhibiting angiogenesis is a potential strategy to attenuate the recurrence and metastasis of TNBC. HTPM&AgNPs-gel is a promising anticancer agent for TNBC as a local postoperative treatment.
References provided by Crossref.org